Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens

The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure

Sanofi acquires rights to develop and commercialize Aficamten in Greater China

In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China

Schizophrenia in Children: Understanding Early-Onset Schizophrenia

Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia

Lonza expands capsule manufacturing capacity in India and China

New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou

Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ

The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer

AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia

Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion